Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2022
Filing Date: July 22, 2022
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a cover sheet incorporating exhibits by reference.
Exhibits Submitted:
- Exhibit 99.1: Appendix 4C and Quarterly Cash Flow Report
Material Changes
The filing text does not contain specific details regarding material changes versus the prior comparable period. Such details are expected to be contained within the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or unusual items. The registrant is identified as a development stage enterprise, implying a focus on research and development rather than commercial revenue generation.
Investor Verification Checklist
- Review Exhibit 99.1 (Appendix 4C and Quarterly Cash Flow Report) for actual financial data, as the cover letter contains no figures.
- Verify the company's cash runway given its status as a development stage enterprise.
- Confirm the incorporation of this report into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-251647, 333-249311, 333-231417, 333-250076).